Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2021

View Archived Issues

Surface Ophthalmics initiates phase II study of SURF-100 for chronic dry eye disease

Gray matter damage in MS starts at synapses

Few-shot learning enhances biomarker identification

CARB-X funding supports Lumen's development of immunotherapy to prevent diarrheal diseases

Contradictory results for FCGR2C gene allele regarding HIV-1 infection risk

PHA-121 demonstrates promising safety and PK profile in phase I study

Final analysis data presented from BLAZE-1 phase II/III study in mild-to-moderate COVID-19

BREEZE study of Tyvaso DPI dry powder formulation meets primary endpoint

PRV-3279 prevents immunogenicity in a preclinical model of gene therapy for Pompe disease

Tempol decreases cytokines from stimulated cells from patients with COVID-19

Sunshine Lake Pharma patents SGLT-1 inhibitors

EyePoint initiates phase I study of EYP-1901 for the treatment of wet AMD

ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors

Positive GLP toxicology study results presented for CBX-12

APX-005M regimen is active and tolerable in metastatic pancreatic adenocarcinoma trial

Idorsia Pharmaceuticals presents IDO1 and TDO inhibitors

FDA clears IND application for PBFT-02 gene therapy candidate

Sapience Therapeutics divulges BCL9 mimetic peptides for cancer

FDA approves IND application for Zofin in COPD

Progen patents new fusion proteins for allergic diseases

PF-06826647 is safe and significantly improves disease activity in subjects with plaque psoriasis

Novavax reports phase III data from U.K. trial of COVID-19 vaccine NVX-CoV2373

FDA lifts clinical hold on phase I/II trial of BPX-601

Kintor cleared to begin Brazilian trial of proxalutamide for hospitalized COVID-19 patients

Reduced TBX15 expression is a prognostic marker in patients with HCC

Macrophages key to liver cells relaxin'

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...